Drug
Enpatoran clinical trials
Also written M5049.
- studies test it
- 12
- open now
- 3
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the enpatoran studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
12 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 4
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
EMD Serono Research & Development Institute, Inc. (6) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (5) · Merck KGaA, Darmstadt, Germany (1)
Studies
Open first, then newest update. How each study uses enpatoran is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseRecruitingPhase 3EMD Serono Research & Development Institute, Inc.NCT07332481Written as Enpatoran
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)RecruitingPhase 3EMD Serono Research & Development Institute, Inc.NCT07355218Written as Enpatoran
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]Not yet recruitingPhase 3EMD Serono Research & Development Institute, Inc.NCT07840287Written as Enpatoran
- The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Active, not recruitingPhase 2Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT05540327Written as M5049 low dose
- Study of M5049 in DM and PM Participants (NEPTUNIA)TerminatedPhase 2EMD Serono Research & Development Institute, Inc.NCT05650567Written as M5049 dose
- Effect of Renal Impairment on Enpatoran PharmacokineticsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT06589713Written as Enpatoran
- The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)CompletedPhase 2EMD Serono Research & Development Institute, Inc.NCT05162586Written as Enpatoran low dose
- A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy ParticipantsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT06589726Written as Enpatoran low dose
- Study of M5049 in CLE and SLE ParticipantsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04647708Written as M5049
- Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)CompletedPhase 2EMD Serono Research & Development Institute, Inc.NCT04448756Written as M5049
- Study of M5049 in Healthy Japanese and Caucasian ParticipantsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04880213Written as M5049
- Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy ParticipantsCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03676322Written as M5049
Given in every arm · 1 — enpatoran is usual care beside what is tested
Codes
What other systems call enpatoran · ClinicalTrials.gg INT002188
- MeSH (NLM) C000732013enpatoranOne source NLM
- UNII (FDA) 7CZ390V26XENPATORANConfirmed FDA, NLM
- NCI Thesaurus C177069EnpatoranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732013 | enpatoran | One source NLM |
| UNII (FDA) | 7CZ390V26X | ENPATORAN | Confirmed FDA, NLM |
| NCI Thesaurus | C177069 | Enpatoran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.